Nephrocare Health Services (NEPHROPLUS) Q4 24/25 earnings summary

Executive summary

• FY25 delivered strong growth: consolidated revenue rose 33.5% to ₹7,558.12m and PAT increased 91.0% to ₹670.96m; India and international dialysis services contributed to performance.

• Operations span dialysis clinics and services in India and international markets, including the Philippines and Uzbekistan; the strategic focus is expansion, clinical quality, digital health and partnerships.

Financial highlights

• Consolidated revenue from operations was ₹7,558.12m vs ₹5,661.55m; PBT ₹874.37m vs ₹331.61m; PAT ₹670.96m vs ₹351.33m in FY24.

• Consolidated EBITDA was ₹1,807.40m vs ₹1,094.53m; basic EPS ₹8.28 vs ₹4.55 and diluted EPS ₹8.01 vs ₹4.40.

• Standalone revenue was ₹5,435.97m, up 24.6%; PBT ₹453.60m vs ₹2.17m and PAT ₹342.36m vs ₹38.82m.

• Consolidated operating cash flow was ₹1,353.47m vs ₹722.80m; cash and cash equivalents ended FY25 at ₹1,258.17m vs ₹611.51m.

• Consolidated revenue included ₹55.34m of liabilities no longer required written back, compared with ₹93.10m in FY24.

Outlook and guidance

• Priorities are to expand across India and key international markets, strengthen clinical quality, invest in digital health solutions and build strategic partnerships to improve access and patient outcomes.

• No numerical FY26 guidance is stated; the outlook emphasizes sustaining long-term growth through brand strength, a scalable operating model and operational excellence.